Table 4.
Antifungal treatment of patients with fungemia
| Treatment parameter | No. (%) of cases or % of cases (no. of cases with change/total no. of cases)b |
||||
|---|---|---|---|---|---|
| Amphotericin B formulation | Caspofungin | Fluconazole | Voriconazole | Total | |
| First choice | 48 (17) | 63 (23) | 159 (57) | 8 (3) | 278 |
| No change | 35 (73) | 48 (76) | 90 (57) | 6/8 | 179 (64) |
| Suboptimal initial therapya | 0 (0) | 3 (5) | 33 (21) | 6/8 | 42 (15) |
| Antifungal modifications upon species identification | |||||
| Step-down for C. albicans infection | 20 (4/20) | 15 (4/26) | NA | 1/2 | 19 (9/48) |
| Change of fluconazole for C. glabrata infection | NA | NA | 56 (15/27) | NA | 56 (15/27) |
a
Initial antifungal therapy was considered suboptimal for the following drug-bug combinations: fluconazole and C. glabrata (27), C. krusei (3), S. cerevisiae (1), or Trichosporon spp. (1); caspofungin and C. parapsilosis (2) or Fusarium spp. (1); and voriconazole and C. glabrata (1) or C. krusei (5).
b
NA, not applicable.